919797-20-9

Basic information

• Product Name: 25I-NBOH HCL
• Synonyms: 25I-NBOH HCL;Phenol, 2-[[[2-(4-iodo-2,5-diMethoxyphenyl)ethyl]aMino]Methyl]-;2-[[[2-(4-Iodo-2,5-dimethoxyphenyl)ethyl]amino]methyl]phenol;25I-NBOH whatsapp;U4TDP u4tdp;Good quality and high purity U4TDP u4tdp CAS NO.919797-20-9;U4TDP U4tdp CAS NO.919797-20-9
• CAS NO: 919797-20-9
• Molecular Formula: C17H20INO3
• Molecular Weight: 413.25007
• Product Categories: 25I-NBOH
• Mol File: 919797-20-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 497.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.493±0.06 g/cm3(Predicted)
• PKA: 10.37±0.30(Predicted)
• CAS DataBase Reference: 25I-NBOH HCL(CAS DataBase Reference)
• NIST Chemistry Reference: 25I-NBOH HCL(919797-20-9)
• EPA Substance Registry System: 25I-NBOH HCL(919797-20-9)

Safety Data

• Hazardous Substances Data: 919797-20-9(Hazardous Substances Data)

Usage

General Description

25I-NBOH HCL, also known as 2C-I-NBOMe, is a potent hallucinogenic drug that belongs to the phenethylamine class of chemicals. It is a derivative of the psychedelic drug 2C-I and is known for its powerful effects on perception, mood, and cognition. 25I-NBOH HCL is a highly potent agonist at serotonin receptor sites, particularly the 5-HT2A receptor, which is responsible for its psychedelic effects. This chemical is often sold as a research chemical or designer drug and is not approved for human consumption. It is important to note that 25I-NBOH HCL has been associated with serious adverse effects, including seizures, cardiovascular complications, and even death, and should be used with extreme caution.

Upstream product

• 1043869-10-8 N-(tert-butoxycarbonyl)-N-(2-hydroxybenzyl)-2-(4-iodo-2-hydroxy-5-methoxyphenyl)ethylamine 
• 74-88-4 methyl iodide 
• 1216821-16-7 tert-butyl N-[2-(2,5-dimethoxy-4-iodophenyl)ethyl]carbamate 
• 69587-11-7 2-(4-iodo-2,5-dimethoxyphenyl)ethylamine 
• 90-02-8 salicylaldehyde 
• 10538-49-5 3-(2,5-dimethoxyphenyl)propanoic acid 
• 3600-86-0 2,5-dimethoxyphenethylamine 
• 108536-18-1 β-dimethoxy-2,5 phenyl nitro ethylene 
• 14438-63-2 1-(2,5-dimethoxyphenyl)-2-nitroethanol 
• 93-02-7 2,5-dimethoxybenzaldehyde 
• 64584-32-3 4-iodo-2,5-dimethoxy-β-phenethylamine hydrochloride 

Relevant articles and documents

Synthesis of 25X-BOMes and 25X-NBOHs (X = H, I, Br) for pharmacological studies and as reference standards for forensic purposes

An expeditious method is reported for the synthesis of three NBOHs (25H-, 25I- and 25B-NBOH; 9–38% overall yield) and three NBOMes (25H-, 25I- and 25B-NBOMe; 7–33% overall yield) from salicylaldehyde and 2-methoxyaldehyde, respectively. The X-ray structures of 25H-, 25I- and 25B-NBOH.HCl were also determined. Our approach should provide a general entry for preparing such a class of substances for pharmacological and forensic purposes.

Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists

N-Benzyl substitution of 5-HT2A receptor agonists of the phenethylamine structural class of psychedelics (such as 4-bromo-2,5- dimethoxyphenethylamine, often referred to as 2C-B) confer a significant increase in binding affinity as well as functional activity of the receptor. We have prepared a series of 48 compounds with structural variations in both the phenethylamine and N-benzyl part of the molecule to determine the effects on receptor binding affinity and functional activity at 5-HT2A and 5-HT2C receptors. The compounds generally had high affinity for the 5-HT2A receptor with 8b having the highest affinity at 0.29 nM but with several other compounds also exhibiting subnanomolar binding affinities. The functional activity of the compounds was distributed over a wider range with 1b being the most potent at 0.074 nM. Most of the compounds exhibited low to moderate selectivity (1- to 40-fold) for the 5-HT2A receptor in the binding assays, although one compound 6b showed an impressive 100-fold selectivity for the 5-HT2A receptor. In the functional assay, selectivity was generally higher with 1b being more than 400-fold selective for the 5-HT2A receptor.